Anteris Technologies (AVR.AX)

Executive Summary

Anteris Technologies is an ASX-listed structural heart company developing the DurAVR™ transcatheter aortic valve replacement (TAVR) system, a biomimetic valve designed to replicate native aortic valve hemodynamics. This single-piece, native-shaped design aims to overcome key limitations of current TAVR devices, such as patient-prosthesis mismatch and durability concerns. With an estimated market capitalization of ~$845M, the company is positioned in the high-growth TAVR market, targeting unmet needs in younger, lower-risk patients. Although still in early clinical stages, positive initial outcomes support the technology's potential to disrupt the structural heart landscape. Execution risk remains given competitive pressures and regulatory hurdles, but the unique valve design offers a differentiated value proposition.

Upcoming Catalysts (preview)

• Q3 20261-Year Clinical Outcomes from DurAVR First-in-Human Study70% success
• Q4 2026CE Mark Submission for DurAVR System50% success
• Q1 2027US FDA IDE Approval for Pivotal Trial60% success